Dunlop A. Sinclair's Form 4 filing
Apellis Pharmaceuticals, Inc. (APLS) · filed Oct 2, 2025
- Accession no.
- 0001193125-25-228277
- Filed
- Oct 2, 2025
- Trade date
- Sep 30, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $702.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dunlop A. SinclairCIK 0001721108 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 30, 2025 | Common Stock | SSaleDisposed | −31,092 | $22.58F2 | −$702,057.36 | 33,979 | Indirect | |
| Sep 30, 2025 | Common Stock | JOtherDisposed | −3,837 | $0.00 | $0 | 30,142 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.23 to $22.74, inclusive. The reporting person hereby undertakes to provide, upon request, to the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.